View Exam | PowerPak

1. The most common presentation of multiple sclerosis (MS) is:

A. Relapsing-remitting MS (RRMS) B. Secondary-progressive MS (SPMS) C. Primary-progressive MS (PPMS) D. Progressive-relapsing MS (PRMS)

2. Symptoms of MS include all of the following except:

A. Cognitive disturbances B. Dyspnea C. Muscle spasticity D. Fatigue

3. Which of the following new MS medications is approved for relapsing forms of multiple sclerosis?

A. Dimethyl fumarate (Tecfidera) B. Fingolimod (Gilenya) C. Peginterferon beta-1a (Plegridy) D. All of the above

4. JP is a 25yo female of Northern European descent presenting with worsening of her pre-existing difficulty walking and fatigue. She also has new-onset loss weakness in her left lower extremity that has been present for 4 days with no fever. Which of the following would you use to treat JP's acute exacerbation of MS?

A. Interferon beta (Avonex) B. Methylprednisolone (Solu-Medrol) C. Fingolimod (Gilenya) D. Natalizumab (Tysabri)

5. Which is true of fingolimod (Gilenya)?

A. Blocks pyrimidine synthesis in rapidly dividing cells, inhibits protein tyrosine-kinase and cyclo-oxygenase-2 activity, and decreases the ability of antigen presenting cells to activate T cells B. Sequesters lymphocytes in lymphatic system, decreasing the overall number of lymphocytes in circulation C. Intercalates with DNA strands, causing breaks, and inhibits DNA repair through topoisomerase II D. Inhibits α4-mediated adhesion to leukocytes to their counter-receptors(s) and prevents transmigration of leukocytes across the endothelium into inflamed parenchymal tissue

6. TD is a woman 18 years of age that was recently diagnosed with RRMS. She is very concerned about using injectable medications and questions you about possible oral treatment options. Which of the following MS medications are available in an oral formulation:

A. Dimethyl fumarate (Tecfidera) B. Natalizumab (Tysabri) C. Glatiramer acetate (Copaxone) D. Mitoxantrone (Novantrone)

7. Which of the following medications can be used to improve difficulty walking:

A. Dalfampridine (Ampyra) B. Phenytoin (Dilantin) C. Oxybutynin (Ditropan) D. Methylphenidate (Ritalin)

8. Adherence has been shown to reduce all of the following except:

A. Relapses B. Hospital visits C. Hospital admissions D. Adverse effects

9. All of the following are barriers to adherence EXCEPT:

A. Side effects B. Patient assistance programs C. Frequency of administration D. Cost

10. According to the FDA, which of the following aspects of active ingredient sameness has Glatopa demonstrated in comparison with the referenced listed drug/innovator product Copaxone:

A. Equivalent fundamental reaction scheme B. Equivalent physicochemical properties including composition C. Equivalent structural signatures for polymerization and depolymerization D. All of the above

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. The most common presentation of multiple sclerosis (MS) is:

2. Symptoms of MS include all of the following except:

3. Which of the following new MS medications is approved for relapsing forms of multiple sclerosis?

5. Which is true of fingolimod (Gilenya)?

6. TD is a woman 18 years of age that was recently diagnosed with RRMS. She is very concerned about using injectable medications and questions you about possible oral treatment options. Which of the following MS medications are available in an oral formulation:

7. Which of the following medications can be used to improve difficulty walking:

8. Adherence has been shown to reduce all of the following except:

9. All of the following are barriers to adherence EXCEPT:

10. According to the FDA, which of the following aspects of active ingredient sameness has Glatopa demonstrated in comparison with the referenced listed drug/innovator product Copaxone:

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. The most common presentation of multiple sclerosis (MS) is:

2. Symptoms of MS include all of the following except:

3. Which of the following new MS medications is approved for relapsing forms of multiple sclerosis?

5. Which is true of fingolimod (Gilenya)?

6. TD is a woman 18 years of age that was recently diagnosed with RRMS. She is very concerned about using injectable medications and questions you about possible oral treatment options. Which of the following MS medications are available in an oral formulation:

7. Which of the following medications can be used to improve difficulty walking:

8. Adherence has been shown to reduce all of the following except:

9. All of the following are barriers to adherence EXCEPT:

10. According to the FDA, which of the following aspects of active ingredient sameness has Glatopa demonstrated in comparison with the referenced listed drug/innovator product Copaxone:

« Return to Activity

Customers who Purchased
this Activity also Purchased